



BRITISH COLUMBIA
CENTRE *for* EXCELLENCE
in HIV/AIDS

B.C. HIV/AIDS Drug Treatment Program

Monthly Report

July 2020





© 2020 BC Centre for Excellence in HIV/AIDS

DISCLAIMER: This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

BC Centre for Excellence in HIV/AIDS Drug Treatment Program

St. Paul's Hospital
608 - 1081 Burrard Street
Vancouver, BC
V6Z 1Y6

Tel: 604.806.8515
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222
Website: www.cfenet.ubc.ca
Email: info@cfenet.ubc.ca

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to HIV-infected persons throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





TABLE OF CONTENTS

1. List of Figures

- 1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2012 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





Table of Contents, cont'd...

3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

4. Health Authority Tables

INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries

FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries

VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries

NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Gender
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries

ABORIGINAL

- 4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of men and women on antiretroviral therapy in British Columbia by Health Authority

July 2020

N = 7348



Health Authority	Male	Female	All
FRASER	1442	440	1882
INTERIOR	420	103	523
NORTHERN	139	91	230
VANCOUVER COASTAL	3305	445	3750
VANCOUVER ISLAND	780	154	934
	6086	1233	7319
		Unknown/not stated:	29
		Total:	7348

Definitions:


On antiretroviral therapy defined as being on treatment in the current month

Unknown/not stated defined as being on treatment in the current month, and city of residence unknown






1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (July 2015 - July 2020)






1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class (July 2015 - July 2020)






1.4 BC-CfE Enrollment: Net Number of New Antiretroviral Participants (July 2015 - July 2020)






1.5 BC-CfE Enrollment: New Antiretroviral Participants (July 2015 - July 2020)






1.6 Percent Distribution of Active Participants by CD4 Count
(July 2015 - July 2020)






1.7 Percent Distribution of Inactive Participants by CD4 Count (July 2015 - July 2020)






1.8 Active and Inactive Participants (July 2015 - July 2020)






1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (July 2015 - July 2020)






1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (July 2015 - July 2020)






1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT (July 2015 - July 2020)






1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (July 2015 - July 2020)






1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(July 2015 - July 2020)






1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (July 2015 - July 2020)






1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(July 2015 - July 2020)






1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (July 2015 - July 2020)






1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by INGREDIENT

(July 2015 - July 2020)






1.18 Baseline CD4 for Antiretroviral First Starts
(July 2015 - July 2020)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (July 2015 - July 2020)






1.20 Cumulative Resistance Testing Results by Resistance Category (July 2015 - July 2020)





1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (July 2015 - July 2020)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2020
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	28	5	0	5	2	595	5	<40	3
1988	29	5	0	5	3	420	4	<40	3
1989	27	53	1	54	33	440	47	<40	3
1990	26	54	1	55	29	570	45	<40	3
1991	26	36	3	39	17	620	30	<40	3
1992	26	61	5	66	27	620	53	<40	3
1993	25	124	15	139	95	550	119	<40	3
1994	23	79	13	92	56	545	78	<40	3
1995	23	130	20	150	94	580	123	<40	3
1996	21	330	49	379	219	600	316	<40	3
1997	20	271	34	305	193	660	251	<40	3
1998	19	193	44	237	141	610	195	<40	3
1999	19	158	37	195	116	605	159	<40	3
2000	19	119	33	152	95	610	122	<40	3
2001	19	115	28	143	88	570	117	<40	3
2002	17	120	25	145	87	570	112	<40	3
2003	17	147	27	174	102	605	141	<40	3
2004	16	152	38	190	121	600	151	<40	3
2005	15	184	46	230	144	610	176	<40	3
2006	14	179	39	218	132	610	179	<40	3
2007	13	240	47	287	173	630	232	<40	3
2008	12	270	66	336	220	640	277	<40	3
2009	11	300	63	363	228	630	295	<40	3
2010	10	270	72	342	203	650	271	<40	3
2011	9	319	70	389	241	670	314	<40	3
2012	8	267	66	333	205	720	260	<40	3
2013	7	263	66	329	201	690	266	<40	3
2014	6	281	53	334	191	690	261	<40	3
2015	5	284	47	331	205	690	265	<40	3
2016	4	271	52	323	190	680	252	<40	3
2017	3	223	34	257	177	610	215	<40	3
2018	2	201	53	254	160	664	216	<40	3

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2020
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4		Current PVL		Current ARV Median
					(n)	Median	(n)	Median	
2019	1	235	51	286	205	630	247	<40	3
2020	0	146	35	181	152	610	168	<40	3
Total:		6085	1233	7318					

Definitions:

On treatment defined as being on ARV therapy in the specified month and not reported deceased

Duration defined as cumulative years on ARV therapy, excluding periods of treatment interruption

Current CD4 and PVL tests defined as tests done in the last 6 months (most recent)

Current ARV defined as number of ARV drugs in the current regimen





2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	7393	787	2456	<40	2146	610
FEB-2019	7368	793	1854	<40	1583	620
MAR-2019	7407	790	2085	<40	1753	610
APR-2019	7358	796	2141	<40	1746	610
MAY-2019	7416	791	2127	<40	1766	620
JUN-2019	7358	803	1926	<40	1593	620
JUL-2019	7370	810	2111	<40	1695	620
AUG-2019	7366	807	2106	<40	1621	600
SEP-2019	7338	805	2011	<40	1568	600
OCT-2019	7389	784	2140	<40	1745	620
NOV-2019	7342	780	2026	<40	1580	630
DEC-2019	7342	777	1700	<40	1292	610
JAN-2020	7357	774	2227	<40	1714	610
FEB-2020	7330	778	1882	<40	1407	628
MAR-2020	7387	769	1628	<40	1191	620
APR-2020	7411	771	767	<40	560	600
MAY-2020	7405	776	1186	<40	848	605
JUN-2020	7381	783	1558	<40	1064	620
JUL-2020	7348	794	1917	<40	1343	620

Definitions:

Active patient defined as being on ARV treatment in the specified month

Therapy days defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

PVL and CD4 tests defined as tests done in the specified month





2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2019	627	193	73	73	65	350
FEB-2019	658	156	75	108	66	590
MAR-2019	629	167	74	636	61	400
APR-2019	671	157	81	<50	71	480
MAY-2019	617	201	78	87	69	450
JUN-2019	680	158	79	<40	72	530
JUL-2019	668	161	71	<40	58	525
AUG-2019	687	166	81	<40	68	515
SEP-2019	717	152	96	<40	79	580
OCT-2019	659	194	81	102	69	470
NOV-2019	680	180	69	<40	59	560
DEC-2019	667	180	58	<40	49	480
JAN-2020	641	191	71	255	47	460
FEB-2020	681	178	72	<40	58	480
MAR-2020	639	195	54	<40	37	470
APR-2020	615	211	28	116	20	545
MAY-2020	630	202	43	<40	31	490
JUN-2020	662	190	58	<40	45	480
JUL-2020	732	163	74	<40	57	620

Definitions:

Inactive patient defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

Days off therapy defined as number of days elapsed since last ARV treatment

PVL and CD4 tests defined as tests done in the specified month





2.4 BC-CfE Enrollment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2019	7364	627	14	20	191	159	35	13564
FEB-2019	7349	658	7	16	160	181	-15	13593
MAR-2019	7371	629	15	13	187	150	22	13613
APR-2019	7325	671	10	15	152	182	-46	13641
MAY-2019	7389	617	11	21	197	137	64	13683
JUN-2019	7329	680	14	13	136	191	-60	13704
JUL-2019	7343	668	13	13	181	164	14	13727
AUG-2019	7338	687	12	18	170	174	-5	13763
SEP-2019	7310	717	14	15	181	204	-28	13790
OCT-2019	7323	659	3	13	223	150	13	13819
NOV-2019	7316	680	9	17	165	170	-7	13852
DEC-2019	7311	667	8	12	164	157	-5	13879
JAN-2020	7329	641	10	12	183	155	18	13902
FEB-2020	7296	681	12	19	141	172	-33	13938
MAR-2020	7358	639	14	23	210	153	62	13974
APR-2020	7384	615	12	8	160	126	26	13999
MAY-2020	7384	630	10	15	131	132	0	14024
JUN-2020	7356	662	8	9	124	148	-28	14041
JUL-2020	7318	732	15	12	159	190	-38	14073

Definitions:

Currently on ARV Therapy defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

Currently off ARV Therapy defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past, and had contact with the program in the past 5 years

Deceased defined as deceased in the specified month, and being on ARV treatment in the previous month

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Experienced Starts defined as starting ARV treatment in the specified month, but previously being treated with ARVs

New Inactive defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

Net Change is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2019	55	6800	485	53	7393	0.74%	91.98%	6.56%	0.72%	100.00%
FEB-2019	54	6775	490	49	7368	0.73%	91.95%	6.65%	0.67%	100.00%
MAR-2019	60	6808	489	50	7407	0.81%	91.91%	6.60%	0.68%	100.00%
APR-2019	57	6764	489	48	7358	0.77%	91.93%	6.65%	0.65%	100.00%
MAY-2019	56	6824	491	45	7416	0.76%	92.02%	6.62%	0.61%	100.00%
JUN-2019	58	6771	481	48	7358	0.79%	92.02%	6.54%	0.65%	100.00%
JUL-2019	61	6772	489	48	7370	0.83%	91.89%	6.64%	0.65%	100.00%
AUG-2019	60	6775	481	50	7366	0.81%	91.98%	6.53%	0.68%	100.00%
SEP-2019	57	6744	486	51	7338	0.78%	91.91%	6.62%	0.70%	100.00%
OCT-2019	61	6788	488	52	7389	0.83%	91.87%	6.60%	0.70%	100.00%
NOV-2019	60	6746	486	50	7342	0.82%	91.88%	6.62%	0.68%	100.00%
DEC-2019	61	6755	478	48	7342	0.83%	92.00%	6.51%	0.65%	100.00%
JAN-2020	60	6757	484	56	7357	0.82%	91.84%	6.58%	0.76%	100.00%
FEB-2020	59	6736	476	59	7330	0.80%	91.90%	6.49%	0.80%	100.00%
MAR-2020	60	6790	486	51	7387	0.81%	91.92%	6.58%	0.69%	100.00%
APR-2020	61	6817	483	50	7411	0.82%	91.98%	6.52%	0.67%	100.00%
MAY-2020	60	6814	481	50	7405	0.81%	92.02%	6.50%	0.68%	100.00%
JUN-2020	59	6786	485	51	7381	0.80%	91.94%	6.57%	0.69%	100.00%
JUL-2020	61	6768	471	48	7348	0.83%	92.11%	6.41%	0.65%	100.00%

Definitions:

Number of Drugs is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)





2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT

	lamivudine		abacavir		zidovudine		stavudine		didanosine		tenofovir <TAF>		tenofovir <TDF>	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	8 23%	3467 48%	7 20%	3254 45%	1 3%	45 1%	0 0%	4 0%	0 0%	1 0%	1 3%	519 7%	26 74%	3358 47%
FEB-2019	13 45%	3457 48%	12 41%	3256 45%	0 0%	44 1%	0 0%	1 0%	0 0%	1 0%	3 10%	541 8%	13 45%	3306 46%
MAR-2019	6 30%	3470 48%	6 30%	3274 45%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 10%	559 8%	12 60%	3305 46%
APR-2019	12 43%	3469 48%	12 43%	3278 46%	0 0%	43 1%	0 0%	2 0%	0 0%	0 0%	2 7%	586 8%	14 50%	3245 45%
MAY-2019	14 34%	3498 48%	14 34%	3308 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	4 10%	593 8%	23 56%	3258 45%
JUN-2019	3 14%	3479 49%	3 14%	3291 46%	0 0%	43 1%	0 0%	2 0%	0 0%	1 0%	2 10%	608 8%	16 76%	3198 45%
JUL-2019	8 36%	3504 49%	8 36%	3325 46%	0 0%	38 1%	0 0%	1 0%	0 0%	1 0%	1 5%	625 9%	13 59%	3177 44%
AUG-2019	14 39%	3515 49%	12 33%	3340 47%	2 6%	41 1%	0 0%	1 0%	0 0%	1 0%	2 6%	630 9%	20 56%	3144 44%
SEP-2019	5 19%	3494 49%	5 19%	3318 46%	0 0%	39 1%	0 0%	1 0%	0 0%	1 0%	5 19%	653 9%	17 63%	3121 44%
OCT-2019	4 14%	3513 49%	2 7%	3331 46%	0 0%	38 1%	0 0%	1 0%	0 0%	1 0%	1 4%	668 9%	23 82%	3142 44%
NOV-2019	8 24%	3458 48%	7 21%	3281 46%	1 3%	37 1%	0 0%	1 0%	0 0%	1 0%	6 18%	728 10%	19 58%	3113 44%
DEC-2019	1 4%	3436 48%	1 4%	3258 46%	0 0%	37 1%	0 0%	1 0%	0 0%	1 0%	13 48%	855 12%	13 48%	3051 43%
JAN-2020	2 9%	3402 47%	2 9%	3226 45%	0 0%	34 0%	0 0%	1 0%	0 0%	0 0%	9 39%	1024 14%	12 52%	2962 41%
FEB-2020	3 8%	3352 47%	3 8%	3180 45%	0 0%	33 0%	0 0%	1 0%	0 0%	0 0%	16 44%	1169 16%	17 47%	2825 40%
MAR-2020	5 14%	3325 46%	5 14%	3160 44%	1 3%	34 0%	0 0%	1 0%	0 0%	0 0%	20 56%	1326 18%	11 31%	2719 38%
APR-2020	6 24%	3299 46%	5 20%	3138 43%	1 4%	35 0%	0 0%	0 0%	0 0%	0 0%	8 32%	1402 19%	11 44%	2639 37%
MAY-2020	1 4%	3276 45%	0 0%	3114 43%	0 0%	36 0%	0 0%	0 0%	0 0%	0 0%	13 54%	1482 21%	11 46%	2599 36%
JUN-2020	5 29%	3246 45%	5 29%	3084 43%	0 0%	33 0%	0 0%	0 0%	0 0%	0 0%	4 24%	1587 22%	8 47%	2523 35%
JUL-2020	6 19%	3208 45%	4 13%	3047 43%	2 6%	33 0%	0 0%	0 0%	0 0%	0 0%	14 44%	1697 24%	12 38%	2424 34%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





Monthly Report

2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (continued)

	emtricitabine			
	Initial		All	
JAN-2019	27	77%	3697	51%
FEB-2019	16	55%	3674	51%
MAR-2019	14	70%	3702	51%
APR-2019	16	57%	3662	51%
MAY-2019	27	66%	3689	51%
JUN-2019	18	86%	3643	51%
JUL-2019	14	64%	3650	51%
AUG-2019	22	61%	3626	51%
SEP-2019	22	81%	3622	51%
OCT-2019	24	86%	3663	51%
NOV-2019	25	76%	3671	51%
DEC-2019	26	96%	3713	52%
JAN-2020	21	91%	3762	52%
FEB-2020	33	92%	3781	53%
MAR-2020	30	83%	3855	54%
APR-2020	19	76%	3890	54%
MAY-2020	23	96%	3918	54%
JUN-2020	12	71%	3930	55%
JUL-2020	26	81%	3948	55%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.7 Number of Participants on Protease Inhibitor by INGREDIENT

	fosamprenavir		atazanavir		darunavir		lopinavir		nelfinavir		ritonavir		saquinavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	6 0%	1 8%	1097 40%	11 92%	1475 54%	0 0%	140 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
FEB-2019	0 0%	5 0%	2 18%	1069 40%	9 82%	1472 55%	0 0%	138 5%	0 0%	0 0%	0 0%	1 0%	0 0%	9 0%
MAR-2019	0 0%	5 0%	2 40%	1053 39%	3 60%	1486 55%	0 0%	132 5%	0 0%	1 0%	0 0%	1 0%	0 0%	7 0%
APR-2019	0 0%	5 0%	1 10%	1027 39%	7 70%	1477 56%	2 20%	132 5%	0 0%	2 0%	0 0%	1 0%	0 0%	7 0%
MAY-2019	0 0%	5 0%	1 8%	1033 39%	11 92%	1478 56%	0 0%	130 5%	0 0%	2 0%	0 0%	1 0%	0 0%	6 0%
JUN-2019	0 0%	5 0%	0 0%	1001 39%	9 100%	1464 57%	0 0%	119 5%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
JUL-2019	0 0%	5 0%	0 0%	981 38%	6 100%	1482 58%	0 0%	111 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
AUG-2019	0 0%	5 0%	0 0%	968 38%	11 92%	1459 57%	1 8%	112 4%	0 0%	1 0%	0 0%	1 0%	0 0%	5 0%
SEP-2019	0 0%	4 0%	1 8%	954 37%	12 92%	1481 58%	0 0%	110 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
OCT-2019	0 0%	4 0%	1 7%	957 37%	13 93%	1489 58%	0 0%	109 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
NOV-2019	0 0%	4 0%	0 0%	940 37%	3 100%	1469 58%	0 0%	101 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
DEC-2019	0 0%	4 0%	0 0%	923 37%	7 100%	1466 59%	0 0%	100 4%	0 0%	1 0%	0 0%	1 0%	0 0%	6 0%
JAN-2020	0 0%	2 0%	0 0%	910 37%	6 86%	1466 59%	1 14%	96 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
FEB-2020	0 0%	2 0%	1 11%	873 36%	8 89%	1454 60%	0 0%	96 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
MAR-2020	0 0%	2 0%	1 10%	860 36%	9 90%	1434 60%	0 0%	93 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
APR-2020	0 0%	2 0%	0 0%	839 36%	4 80%	1413 60%	1 20%	93 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
MAY-2020	0 0%	2 0%	1 10%	835 36%	9 90%	1413 60%	0 0%	89 4%	0 0%	0 0%	0 0%	0 0%	0 0%	6 0%
JUN-2020	0 0%	2 0%	2 33%	813 35%	4 67%	1389 61%	0 0%	86 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%
JUL-2020	0 0%	1 0%	0 0%	781 35%	8 100%	1364 61%	0 0%	81 4%	0 0%	0 0%	0 0%	1 0%	0 0%	6 0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





Monthly Report

2.7 Number of Participants on Protease Inhibitor by INGREDIENT (continued)

	tipranavir			
	Initial		All	
JAN-2019	0	0%	1	0%
FEB-2019	0	0%	1	0%
MAR-2019	0	0%	1	0%
APR-2019	0	0%	1	0%
MAY-2019	0	0%	1	0%
JUN-2019	0	0%	1	0%
JUL-2019	0	0%	1	0%
AUG-2019	0	0%	1	0%
SEP-2019	0	0%	1	0%
OCT-2019	0	0%	1	0%
NOV-2019	0	0%	1	0%
DEC-2019	0	0%	1	0%
JAN-2020	0	0%	1	0%
FEB-2020	0	0%	1	0%
MAR-2020	0	0%	1	0%
APR-2020	0	0%	1	0%
MAY-2020	0	0%	0	0%
JUN-2020	0	0%	1	0%
JUL-2020	0	0%	1	0%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





2.8 Number of Participants on Non-Nucleosides by INGREDIENT

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	0 0%	4 80%	669 35%	0 0%	221 12%	1 20%	695 37%	0 0%	318 17%
FEB-2019	0 0%	0 0%	2 67%	667 35%	1 33%	226 12%	0 0%	683 36%	0 0%	313 17%
MAR-2019	0 0%	0 0%	3 75%	660 35%	0 0%	223 12%	1 25%	680 36%	0 0%	322 17%
APR-2019	0 0%	0 0%	4 100%	645 35%	0 0%	222 12%	0 0%	677 36%	0 0%	320 17%
MAY-2019	0 0%	0 0%	5 100%	647 35%	0 0%	217 12%	0 0%	672 36%	0 0%	322 17%
JUN-2019	0 0%	0 0%	3 75%	633 35%	0 0%	211 12%	0 0%	664 36%	1 25%	320 18%
JUL-2019	0 0%	1 0%	2 100%	633 35%	0 0%	209 11%	0 0%	657 36%	0 0%	322 18%
AUG-2019	0 0%	1 0%	2 100%	624 35%	0 0%	205 11%	0 0%	647 36%	0 0%	324 18%
SEP-2019	0 0%	1 0%	4 80%	607 34%	0 0%	207 12%	0 0%	622 35%	1 20%	324 18%
OCT-2019	0 0%	1 0%	6 60%	608 35%	1 10%	209 12%	2 20%	596 34%	1 10%	330 19%
NOV-2019	0 0%	1 0%	5 71%	612 37%	0 0%	208 12%	1 14%	525 31%	1 14%	326 20%
DEC-2019	0 0%	1 0%	3 100%	607 37%	0 0%	203 12%	0 0%	513 31%	0 0%	324 20%
JAN-2020	0 0%	1 0%	2 100%	589 36%	0 0%	202 13%	0 0%	501 31%	0 0%	325 20%
FEB-2020	0 0%	1 0%	4 100%	558 36%	0 0%	198 13%	0 0%	483 31%	0 0%	320 21%
MAR-2020	0 0%	1 0%	4 100%	547 36%	0 0%	195 13%	0 0%	464 31%	0 0%	315 21%
APR-2020	0 0%	1 0%	6 86%	542 36%	0 0%	190 13%	0 0%	456 30%	1 14%	313 21%
MAY-2020	0 0%	1 0%	1 50%	538 36%	0 0%	193 13%	0 0%	452 30%	1 50%	305 20%
JUN-2020	0 0%	1 0%	2 100%	526 36%	0 0%	189 13%	0 0%	448 30%	0 0%	307 21%
JUL-2020	0 0%	3 0%	2 50%	507 35%	0 0%	184 13%	2 50%	439 31%	0 0%	305 21%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT

	bictegravir		dolutegravir		elvitegravir		maraviroc		raltegravir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2019	0 0%	16 0%	15 75%	2429 63%	4 20%	729 19%	0 0%	39 1%	1 5%	651 17%
FEB-2019	0 0%	27 1%	16 73%	2431 63%	5 23%	726 19%	0 0%	40 1%	1 5%	651 17%
MAR-2019	0 0%	27 1%	8 62%	2479 64%	5 38%	745 19%	0 0%	38 1%	0 0%	647 17%
APR-2019	0 0%	27 1%	8 57%	2493 64%	3 21%	736 19%	0 0%	36 1%	3 21%	636 16%
MAY-2019	0 0%	27 1%	19 68%	2554 64%	6 21%	746 19%	0 0%	37 1%	3 11%	634 16%
JUN-2019	0 0%	27 1%	10 77%	2556 65%	3 23%	743 19%	0 0%	37 1%	0 0%	624 16%
JUL-2019	0 0%	27 1%	13 81%	2603 65%	3 19%	755 19%	0 0%	38 1%	0 0%	628 16%
AUG-2019	0 0%	27 1%	24 86%	2647 65%	1 4%	755 19%	0 0%	36 1%	3 11%	625 15%
SEP-2019	0 0%	28 1%	7 47%	2648 65%	6 40%	757 19%	0 0%	37 1%	2 13%	627 15%
OCT-2019	0 0%	28 1%	13 87%	2717 66%	1 7%	758 18%	0 0%	34 1%	1 7%	628 15%
NOV-2019	3 13%	88 2%	16 70%	2741 65%	4 17%	770 18%	0 0%	33 1%	0 0%	621 15%
DEC-2019	12 63%	230 5%	6 32%	2716 64%	1 5%	744 18%	0 0%	33 1%	0 0%	606 14%
JAN-2020	9 50%	421 10%	7 39%	2687 62%	0 0%	707 16%	0 0%	32 1%	2 11%	594 14%
FEB-2020	14 52%	602 14%	11 41%	2644 60%	2 7%	654 15%	0 0%	29 1%	0 0%	576 13%
MAR-2020	19 68%	755 17%	7 25%	2624 58%	1 4%	623 14%	1 4%	30 1%	0 0%	562 12%
APR-2020	7 50%	827 18%	6 43%	2590 57%	1 7%	607 13%	0 0%	29 1%	0 0%	544 12%
MAY-2020	10 56%	912 20%	6 33%	2558 56%	2 11%	597 13%	0 0%	27 1%	0 0%	541 12%
JUN-2020	4 31%	1024 22%	9 69%	2541 55%	0 0%	582 13%	1 8%	28 1%	0 0%	538 12%
JUL-2020	9 38%	1141 24%	10 42%	2514 54%	5 21%	550 12%	0 0%	29 1%	0 0%	527 11%

Definitions:

Initial is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

All is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Class

MON-YYYY	Boosted PI + 2 NRTIs		NNRTI + 2 NRTIs		Integrase + 2 NRTIs		Un-boosted PI + 2 NRTIs		MDRT		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2019	1830	24.75	1481	20.03	3061	41.40	100	1.35	53	0.72	868	11.74
FEB-2019	1802	24.46	1478	20.06	3072	41.69	99	1.34	49	0.67	868	11.78
MAR-2019	1794	24.22	1471	19.86	3124	42.18	98	1.32	50	0.68	870	11.75
APR-2019	1760	23.92	1458	19.82	3135	42.61	100	1.36	48	0.65	857	11.65
MAY-2019	1773	23.91	1448	19.53	3196	43.10	97	1.31	45	0.61	857	11.56
JUN-2019	1738	23.62	1438	19.54	3195	43.42	95	1.29	48	0.65	844	11.47
JUL-2019	1712	23.23	1427	19.36	3236	43.91	92	1.25	48	0.65	855	11.60
AUG-2019	1686	22.89	1402	19.03	3295	44.73	94	1.28	50	0.68	839	11.39
SEP-2019	1697	23.13	1361	18.55	3298	44.94	93	1.27	51	0.70	838	11.42
OCT-2019	1702	23.03	1339	18.12	3357	45.43	93	1.26	52	0.70	846	11.45
NOV-2019	1666	22.69	1272	17.32	3424	46.64	91	1.24	50	0.68	839	11.43
DEC-2019	1643	22.38	1248	17.00	3483	47.44	92	1.25	48	0.65	828	11.28
JAN-2020	1617	21.98	1209	16.43	3562	48.42	87	1.18	56	0.76	826	11.23
FEB-2020	1573	21.46	1154	15.74	3644	49.71	85	1.16	59	0.80	815	11.12
MAR-2020	1540	20.85	1134	15.35	3755	50.83	85	1.15	51	0.69	822	11.13
APR-2020	1524	20.56	1129	15.23	3808	51.38	85	1.15	50	0.67	815	11.00
MAY-2020	1514	20.45	1113	15.03	3833	51.76	83	1.12	50	0.68	812	10.97
JUN-2020	1461	19.79	1087	14.73	3887	52.66	83	1.12	51	0.69	812	11.00
JUL-2020	1427	19.42	1059	14.41	3942	53.65	79	1.08	48	0.65	793	10.79

Definitions:

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month





2.11 Baseline CD4 for Antiretroviral First Starts

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2019	20	3	3	2	4	6	390
FEB-2019	16	1	0	6	4	4	400
MAR-2019	13	1	2	1	5	4	450
APR-2019	15	3	3	1	2	4	340
MAY-2019	21	1	0	6	8	4	440
JUN-2019	13	2	1	1	2	5	430
JUL-2019	13	1	1	1	3	7	530
AUG-2019	18	0	1	6	4	6	390
SEP-2019	15	0	0	2	4	7	530
OCT-2019	13	1	1	4	4	3	380
NOV-2019	17	4	1	1	1	10	520
DEC-2019	12	0	2	4	2	4	350
JAN-2020	12	0	2	1	4	4	490
FEB-2020	19	5	1	5	3	5	320
MAR-2020	23	4	0	3	1	10	550
APR-2020	8	0	0	3	0	5	686
MAY-2020	15	1	0	3	4	7	400
JUN-2020	9	1	0	3	4	1	380
JUL-2020	12	3	0	0	2	4	500

Definitions:

First Starts defined as starting ARV treatment in the specified month for the first time (ARV naive)

Baseline CD4 is defined as most recent CD4 test before ARV start





2.12 DTP Participants with PVL Measurement within previous five years, and never on ART

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2019	12252	3830
FEB-2019	12260	3829
MAR-2019	12290	3859
APR-2019	12316	3882
MAY-2019	12332	3883
JUN-2019	12332	3888
JUL-2019	12349	3903
AUG-2019	12381	3920
SEP-2019	12400	3938
OCT-2019	12434	3962
NOV-2019	12456	3971
DEC-2019	12480	3986
JAN-2020	12535	4032
FEB-2020	12566	4049
MAR-2020	12566	4039
APR-2020	12544	4015
MAY-2020	12534	4003
JUN-2020	12513	3982
JUL-2020	12490	3949

Definitions:

Patients with PVL test are defined as having at least one PVL test within previous five years, and not reported deceased/moved
Never on ART are subset of patients with PVL test, and not being treated with ARVs on or before specified month







3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
July 2020

N = 7348

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY







3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participants

July 2020

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



SURREY BY POSTAL CODE







3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participants

July 2020

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VANCOUVER BY POSTAL CODE







3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participants

July 2020

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



VICTORIA BY POSTAL CODE







3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participants

July 2020

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





4.1 Distribution of Participants in BC-CfE Registries by Age and Gender INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	7	7	*
	35-49	9	10	*
	50+	27	39	*
	Total HSDA:	43	56	29
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	74	98	57	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HSDA:	369	502	282	
THOMPSON/CARIBOO/ SHUSWAP	20-34	18	18	11
	35-49	70	75	57
	50+	110	180	87
	Total HSDA:	198	273	155
Total HA:		684	929	523

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		684	929	523

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	543	739	420
Female	141	190	103

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	523	55	630	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	21	13
	5 years or more	10	6
	<5 years	12	10
	Total HSDA:	43	29
KOOTENAY BOUNDARY	10 years or more	47	35
	5 years or more	16	12
	<5 years	11	10
	Total HSDA:	74	57
OKANAGAN	10 years or more	228	166
	5 years or more	78	63
	<5 years	63	53
	Total HSDA:	369	282
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	110	82
	5 years or more	43	39
	<5 years	45	34
	Total HSDA:	198	155
Total HA:		684	523

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	406	296
	5 years or more	147	120
	<5 years	131	107
Total HA:		684	523

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.3 Distribution of ARV Prescribing Physicians in BC-CfE Registries INTERIOR Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
EAST KOOTENAY	46	64	14	25
KOOTENAY BOUNDARY	73	123	25	44
OKANAGAN	226	939	60	286
THOMPSON/CARIBOO/SHUSWAP	140	524	35	136
Total:	485	1650	134	491

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
EAST KOOTENAY	*
KOOTENAY BOUNDARY	*
OKANAGAN	*
THOMPSON/CARIBOO/SHUSWAP	*
Total:	93

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.4 Distribution of Participants in BC-CfE Registries by Age and Gender FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	7
	20-34	32	34	27
	35-49	97	106	69
	50+	244	322	189
	Total HSDA:	380	469	292
FRASER NORTH	0-19	5	5	*
	20-34	121	121	*
	35-49	337	363	*
	50+	594	927	*
	Total HSDA:	1057	1416	790
FRASER SOUTH	0-19	5	5	*
	20-34	111	113	*
	35-49	326	369	*
	50+	563	833	*
	Total HSDA:	1005	1320	800
Total HA:		2442	3205	1882

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	17	17	13
	20-34	264	268	186
	35-49	760	838	586
	50+	1401	2082	1097
Total HA:		2442	3205	1882

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1853	2456	1442
Female	589	749	440

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	1882	52	630	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	225	171
	5 years or more	77	61
	<5 years	78	60
	Total HSDA:	380	292
FRASER NORTH	10 years or more	604	423
	5 years or more	261	214
	<5 years	192	153
	Total HSDA:	1057	790
FRASER SOUTH	10 years or more	582	457
	5 years or more	218	162
	<5 years	205	181
	Total HSDA:	1005	800
Total HA:		2442	1882

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1411	1051
	5 years or more	556	437
	<5 years	475	394
Total HA:		2442	1882

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





4.6 Distribution of ARV Prescribing Physicians in BC-CfE Registries FRASER Health Authority

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
FRASER EAST	141	513	30	54
FRASER NORTH	253	1581	51	228
FRASER SOUTH	220	1594	48	493
Total:	614	3688	129	775

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
FRASER EAST	199
FRASER NORTH	659
FRASER SOUTH	436
Total:	1294

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		344	494
RICHMOND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		185	235
VANCOUVER	0-19	19	19	7
	20-34	451	466	295
	35-49	1350	1511	950
	50+	2865	4928	2077
	Total HSDA:	4685	6924	3329
Total HA:		5214	7653	3750

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	22	22	9
	20-34	512	528	338
	35-49	1476	1648	1045
	50+	3204	5455	2358
Total HA:		5214	7653	3750

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Unknown	2	2	0
Male	4608	6722	3305
Female	604	929	445

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	3750	54	640	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	193	152
	5 years or more	88	72
	<5 years	63	57
	Total HSDA:	344	281
RICHMOND	10 years or more	102	72
	5 years or more	40	29
	<5 years	43	39
	Total HSDA:	185	140
VANCOUVER	10 years or more	2884	1971
	5 years or more	1074	774
	<5 years	727	584
	Total HSDA:	4685	3329
Total HA:		5214	3750

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	3179	2195
5 years or more	1202	875
<5 years	833	680
Total HA:	5214	3750

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER COASTAL Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH SHORE/COAST GARIBALDI	177	403	56	87
RICHMOND	43	290	10	91
VANCOUVER	625	10968	209	5274
Total:	845	11661	275	5452

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH SHORE/COAST GARIBALDI	6
RICHMOND	5
VANCOUVER	74
Total:	85

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Gender
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		334	471
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		126	169
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		751	1067
Total HA:		1211	1707	934

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
Total HA:		1211	1707	934

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	1005	1410	780
Female	206	297	154

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	934	55	580	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	193	158
	5 years or more	73	58
	<5 years	68	49
	Total HSDA:	334	265
NORTH VANCOUVER ISLAND	10 years or more	73	56
	5 years or more	36	26
	<5 years	17	14
	Total HSDA:	126	96
SOUTH VANCOUVER ISLAND	10 years or more	435	306
	5 years or more	164	142
	<5 years	152	125
	Total HSDA:	751	573
Total HA:		1211	934

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	701	520
	5 years or more	273	226
	<5 years	237	188
Total HA:		1211	934

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.12 Distribution of ARV Prescribing Physicians in BC-CfE Registries
VANCOUVER ISLAND Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
CENTRAL VANCOUVER ISLAND	196	875	78	192
NORTH VANCOUVER ISLAND	147	261	48	79
SOUTH VANCOUVER ISLAND	212	1815	45	554
Total:	555	2951	171	825

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
CENTRAL VANCOUVER ISLAND	49
NORTH VANCOUVER ISLAND	42
SOUTH VANCOUVER ISLAND	113
Total:	204

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.13 Distribution of Participants in BC-CfE Registries by Age and Gender NORTHERN Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	Total HSDA:		43	51
NORTH WEST	20-34	9	10	5
	35-49	17	33	13
	50+	43	67	36
	Total HSDA:		69	110
NORTHERN INTERIOR	0-19	5	5	*
	20-34	23	24	*
	35-49	70	87	*
	50+	95	160	*
	Total HSDA:		193	276
Total HA:		305	437	230

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	*
	20-34	36	38	*
	35-49	106	141	*
	50+	157	252	*
Total HA:		305	437	230

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	185	269	139
Female	120	168	91

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total HA:	230	51	550	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	21	12
	5 years or more	15	9
	<5 years	7	6
	Total HSDA:	43	27
NORTH WEST	10 years or more	34	25
	5 years or more	23	19
	<5 years	12	10
	Total HSDA:	69	54
NORTHERN INTERIOR	10 years or more	80	62
	5 years or more	66	51
	<5 years	47	36
	Total HSDA:	193	149
Total HA:		305	230

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	135	99
	5 years or more	104	79
	<5 years	66	52
Total HA:		305	230

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Treatment Duration defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribing Physicians in BC-CfE Registries
NORTHERN Health Authority**

HSDA of Physician Residency	# of Physicians ever prescribed ARVs	# of Patients ever treated by Physicians	# of Physicians currently prescribing ARVs	# of Patients currently treated by Physicians
NORTH EAST	41	63	6	7
NORTH WEST	83	164	18	35
NORTHERN INTERIOR	116	456	20	189
Total:	240	683	44	231

HSDA of Patient Residency	# of Patients seeking Physician's care out of HA
NORTH EAST	10
NORTH WEST	18
NORTHERN INTERIOR	12
Total:	40

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently prescribing/treated defined as prescribing/being treated in the previous 6 months

of Patients seeking Physician out of HA is defined as patients residing in specified HSDA, but their follow-up physician(s) reside in another HA





4.16 Distribution of Aboriginal Participants in BC-CfE Registries by Health Service Delivery Area and Gender

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	6	10	5
	KOOTENAY BOUNDARY	6	9	6
	OKANAGAN	25	41	16
	THOMPSON/CARIBOO/SHUSWAP	26	48	21
	Total HA:	63	108	48
FRASER	FRASER EAST	36	46	32
	FRASER NORTH	53	89	43
	FRASER SOUTH	80	113	61
	Total HA:	169	248	136
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	24	47	22
	RICHMOND	9	14	6
	VANCOUVER	482	867	378
	Total HA:	515	928	406
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	51	80	42
	NORTH VANCOUVER ISLAND	19	28	13
	SOUTH VANCOUVER ISLAND	42	86	36
	Total HA:	112	194	91
NORTHERN	NORTH EAST	13	15	12
	NORTH WEST	27	58	19
	NORTHERN INTERIOR	77	116	67
	Total HA:	117	189	98
Total:		976	1667	779

Gender	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	615	1068	485
Female	361	599	294

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
Total:	779	52	500	35

* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

Definitions:

Currently treated with ARVs defined as being on ARV therapy in the specified month

Med CD4 and PVL tests defined as most recent tests (as of specified month)





5.1 Drug Names and Definitions

Abacavir (Ziagen, ABC): a NUCLEOSIDE ANALOG from ViiV Healthcare.

Active: persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

Amphotericin B (Fungilin): a drug used for treatment of candidiasis and other fungal infections.

Amprenavir (Agenerase, APV): a PROTEASE INHIBITOR from ViiV Healthcare. No longer marketed in Canada.

Antiretroviral (ARV): a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

Atazanavir (Reyataz, ATV): a PROTEASE INHIBITOR from Bristol-Myers Squibb.

Atovaquone (Mepron): a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

Atripla (ATP): the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

Azithromycin (Zithromax): an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

Bictegravir: an INTEGRASE INHIBITOR from Gilead Sciences.

Boosted PI: a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

CD4 Cell Count: the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

Chemokine Receptor Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

Clarithromycin (Biaxin): an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

Cobicistat: a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

Combination Therapy: initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

Combivir (CBV): the ViiV Healthcare trade name for a tablet containing both ZIDOVUDINE and LAMIVUDINE.

Complera (CPL): the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

Darunavir (Prezista, DRV): a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Deceased: persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.





Monthly Report

Descovy (DSC): the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.

Didanosine (Videx, DDI): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Dolutegravir (Tivicay, DTG): an INTEGRASE INHIBITOR from ViiV Healthcare.

Doravirine: a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

Efavirenz (Sustiva, Auro efavirenz, EFV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

Elvitegravir (EGV): an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

Emtricitabine (FTC): a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

Enfuvirtide (Fuzeon, T20): a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

Entry Inhibitor: a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

Etravirine (Intelence, ETV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

Ethambutol (Myambutol): an antibiotic used in COMBINATION THERAPY for treatment of mycobacterial infections such as tuberculosis and mycobacterium avium complex (MAC).

First started program: a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

Fosamprenavir (Telzir, fAPV): a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

Fusion Inhibitor: a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

Genvoya (GNV): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

Granulocyte Colony Stimulating Factor (GCSF, Neupogen): a natural hormone that stimulates production of granulocytes, a type of white blood cell (leukocyte).

Health Authority: refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

Inactive: persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

Integrase Inhibitor: a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

Kivexa (KIV): the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

Lamivudine (3TC): a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

Lopinavir (Kaletra, LPV/r): a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.





Monthly Report

Maraviroc (Celsentri, MVC): a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

Median (MED) age: median age of participants in the HIV/AIDS Drug Treatment program in that time period.

MDRT: see MULTIPLE DRUG RESCUE THERAPY

Moved out of BC: a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

Moxifloxacin: a fluoroquinolone antibiotic that is used for treatment of mycobacterium avium complex which is resistant to clarithromycin.

Multiple Drug Rescue Therapy (MDRT or Mega-HAART): the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

Nelfinavir (Viracept, NFV): a PROTEASE INHIBITOR from ViiV Healthcare.

Net change: the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

Nevirapine (Viramune, NVP): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

NNRTI: see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

NNRTI / no PI: a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI): a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

NRTI: see NUCLEOSIDE ANALOG.

Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI): a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

Nucleotide Analog: ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

Octreotide Acetate (Sandostatin): a drug used to treat chronic refractory diarrhea.

Odefsey (ODF): the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

One or more PI: a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

Other: an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

Paromomycin (Humatin): an antibiotic used to treat infections caused by intestinal parasites, including AIDS-related cryptosporidiosis.





Pentamidine: an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

PI: see PROTEASE INHIBITOR.

Prezcobix (PZC): the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

Prodrug: a compound that is converted within the body into the active form that has medical effects.

Protease Inhibitor: a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.

Raltegravir (RGV, Isentress): an INTEGRASE INHIBITOR from Merck.

Restarted/ changed therapy (Tx): a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

Rifabutin (Mycobutin): an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

Rilpivirine (Edurant, RPV): a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

Ritonavir (Norvir, RTV): a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

Saquinavir (Invirase, SQV): a PROTEASE INHIBITOR from Hoffman-La Roche.

Stavudine (Zerit, d4T): a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

Stopped all therapies (Tx): a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

Stribild (STR): the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

Tenofovir alafenamide (Tenofovir AF, TAF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF): a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

Tipranavir (Aptivus, TPV): a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

Triple Therapy: the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

Triumeq (TRQ): the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

Trizivir (TRZ): the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

Truvada (TRU): the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.





Monthly Report

Valganciclovir: an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

Viral Load: the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

Zidovudine (Retrovir, AZT): a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

